REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/17/2025
Back to search
Official data from USPTO
SEQOMBIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/18/2025
Trademark type
Word
Nice classes
5
Filing date
02/02/2018
Registration date
11/17/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/17/2020
Last transaction
11/18/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
03
Owner location
INCHEON, KR
Examiner
OSGOOD,KRYSTINA E
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Celltrion, Inc.
Representatives
KISUK LEE HARNESS, DICKEY & PIERCE, PLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of neurogenic detrusor overactivity; drugs being pharmaceutical preparations for the treatment of iron overloadmigraine and diabetes; medicines for the treatment of cardiacneurologicmetabolicgeneticpsychologic and psychiatric diseases and disorders; ethical medicinal preparations for prevention and treatment of low blood pressure; biological preparations for medical purposes for the treatment of infectious diseasestumor-related diseasesauto-immune diseaseshormone-deficiency diseases; pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral diseases; vaccines; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune diseases; anti-infectives; antivirals; antibiotics; antiepileptic drugsanti-epileptic pharmaceutical preparations; dietary supplements; vitamin and mineral preparations for medical use; pharmaceuticalspharmaceutical preparations for the prevention of HIV/AIDS infection; pharmaceuticalspharmaceutical preparations for the treatment of HIV/AIDS
Publications
History of USPTO decisions and trademark events.
29 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/17/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/01/2020
PUBO
PUBLISHED FOR OPPOSITION
09/01/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/27/2020
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/24/2020
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
10/08/2019
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
10/08/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
07/24/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/24/2019
GNSL
LETTER OF SUSPENSION E-MAILED
01/24/2019
CNSL
SUSPENSION LETTER WRITTEN
01/24/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/03/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/02/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/28/2018
GNSL
LETTER OF SUSPENSION E-MAILED
08/28/2018
CNSL
SUSPENSION LETTER WRITTEN
08/28/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/27/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/27/2018
ALIE
ASSIGNED TO LIE
08/23/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/16/2018
GNRT
NON-FINAL ACTION E-MAILED
05/16/2018
CNRT
NON-FINAL ACTION WRITTEN
05/16/2018
DOCK
ASSIGNED TO EXAMINER
05/15/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2018
NWAP
NEW APPLICATION ENTERED
02/06/2018
Continuous trademark protection
Get notified about every new filing that threatens SEQOMBIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.